A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

Phase 2

Completed

Conditions: Androgenetic Alopecia

Interventions: Drug: Minoxidil Solution 5%
Drug: Placebo solution
Drug: CB-03-01 solution

Registration Number: NCT02279823

Lead Sponsor: Intrepid Therapeutics, Inc.

Brief Summary: In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: Male

Target Recruitment: 95

Inclusion Criteria

Subject has mild to moderate androgenetic alopecia (AGA) in temple and vertex region
Subject is willing to maintain the same hairstyle, hair length, and hair color throughout the study
Subject agrees to continue his other general hair care products and regimen for the entire study
Subjects who are sexually active with a female partner must be surgically sterile or agree to use an effective method of birth control from the first administration of the test article until 30 days after the last administration

Exclusion Criteria

Subject has any dermatological disorders of the scalp in the target region with the possibility of interfering with the application of the test article or examination method, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis, scars, or scalp atrophy
Subject has any condition in the opinion of the investigator that could interfere with the evaluation of the test articles or requires the use of interfering topical or systemic therapy (e.g., uncontrolled thyroid disease, certain genetic disorders that involve hair growth or patterns)
Subject has a current or recent history (within 3 months) of hair transplants, hair weaves or non-breathable wigs and hair bonding
Subject has a current or recent history (within 3 months) of active hair loss due to diffuse telogen effluvium, alopecia areata, scarring alopecia, trichotillomania or conditions/diseases other than AGA
Subject has a current or recent history (within 3 months) of severe dietary changes or presenting a history of eating disorder(s)
Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study
Subject is currently enrolled in an investigational drug or device study
Subject has received an investigational drug or been treated with an investigational device within 30 days prior to the initiation of treatment
Subject is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
Subject may be unreliable for the study including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits
The subject has known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test articles or tattoo ink
Subject has used any of the following topical preparations or procedures on the scalp:
- Topical treatments including corticosteroids, pimecrolimus, tacrolimus, minoxidil, hormone therapy, anti-androgens or other agents that are known to affect hair growth in the opinion of the investigator within 12 weeks of the initiation of treatment
- Topical over-the-counter (OTC) or cosmetic treatments known or reasonably believed to affect hair growth (e.g., brands such as Aminexil, Maxilene, Nioxin, Foltene, etc. or hair health or hair growth products with saw palmetto, copper, etc.) in the opinion of the investigator within 4 weeks of the initiation of treatment.
- Scalp procedures (surgical, laser, light or energy treatments, etc.) within 6 months of the initiation of treatment
Subject has used the following systemic medications or procedures:
- Beta blockers, cimetidine, diazoxide, isotretinoin, vitamin A intake above 10000 IU per day or corticosteroids (including intramuscular and intralesional injections) within 12 weeks of the initiation of treatment. Inhaled, intranasal or ocular corticosteroids are allowed if use is stable (stable use is defined as dose and frequency unchanged for at least 4 weeks prior to the initiation of treatment)
- Retinoid, cyclosporine therapy within 6 months of the initiation of treatment
- Finasteride (Propecia®, etc.), dutasteride or a similar product(s) within 12 months of the initiation of treatment
- Chemotherapy, cytotoxic agents or radiation (of the scalp) within 12 months of the initiation of treatment
- Other systemic therapy which may materially affect the subject's hair or hair growth in the opinion of the investigator

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Minoxidil Solution 5%	Minoxidil Solution 5%	Topical solution applied twice daily for 26 weeks
Placebo solution	Placebo solution	Topical solution applied twice daily for 26 weeks
CB-03-01 solution	CB-03-01 solution	Topical solution applied twice daily for 26 weeks

Primary Outcome Measures

Name	Time	Method
Change in Target Area Hair Count (TAHC)	Baseline and Month 6	Changes from Baseline in TAHC \[in number of non-vellus hairs\] using digital image analysis at Month 6.
Subject Self Assessment (Hair Growth Assessment [HGA])	Month 6	The subject's evaluation of treatment benefit via the HGA questionnaires at Month 6. Scalp hair growth is compared from baseline using the following 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3).

Secondary Outcome Measures

Name	Time	Method
Change in Target Area Hair Density (TAHD)	Baseline and Month 6	Changes from Baseline in TAHD \[in intensity units\] using digital image analysis at Month 6.
Investigator's Global Assessment (IGA)	Baseline, Month 2, 4 and 6	Compared to Baseline, the investigator will assess the subject's scalp hair growth using the following 7-point scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (1), moderately increased (2), and greatly increased (3).
Change in Target Area Hair Width (TAHW)	Baseline and Month 6	Changes from Baseline in TAHW \[in μm/cm2\] using digital image analysis at Month 6.
Subject evaluation of treatment benefit via the Hair Growth Index (HGI) and Hair Growth Satisfaction Scale (HGSS) questionnaires	Month 6	The subject's evaluation of treatment benefit via the HGI and HGSS questionnaires at Month 6. HGI: Hair growth is compared from baseline by three questions on a health outcome questionnaire, which are scored using the following 7-point scale: much less (-3), moderately less (-2), slightly less (-1), the same amount (0), slightly more (1), moderately more (2), much more (3). HGSS: Hair appearance/growth is compared from baseline by five questions, which are scored using the following 7-point scale: very dissatisfied (-3), dissatisfied (-2), somewhat dissatisfied (-1), neutral/neither satisfied nor dissatisfied (0), somewhat satisfied (1), satisfied (2), very satisfied (3).

Trial Locations

Locations (3): DermResearch, Inc.
🇺🇸
Austin, Texas, United States
Therapeutics Clinical Research
🇺🇸
San Diego, California, United States
Minnesota Clinical Study Center
🇺🇸
Fridley, Minnesota, United States